FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313555572> ?p ?o ?g. }

• W4313555572 endingPage "231" @default.
• W4313555572 startingPage "219" @default.
• W4313555572 abstract "Development of myelofibrosis (MF) therapeutics has reached fruition as the transformative impact of JAK2 inhibitors in the MPN landscape is complemented/expanded by a profusion of novel monotherapies and rational combinations in the frontline and second line settings. Agents in advanced clinical development span various mechanisms of action (eg, epigenetic or apoptotic regulation), may address urgent unmet clinical needs (cytopenias), increase the depth/duration of spleen and symptom responses elicited by ruxolitinib, improve other aspects of the disease besides splenomegaly/constitutional symptoms (eg, resistance to ruxolitinib, bone marrow fibrosis or disease course), provide personalized strategies, and extend overall survival (OS). Ruxolitinib had a dramatic impact on the quality of life and OS of MF patients. Recently, pacritinib received regulatory approval for severely thrombocytopenic MF patients. Momelotinib is advantageously poised among JAK inhibitors given its differentiated mode of action (suppression of hepcidin expression). Momelotinib demonstrated significant improvements in anemia measures, spleen responses, and MF-associated symptoms in MF patients with anemia; and will likely receive regulatory approval in 2023. An array of other novel agents combined with ruxolitinib, such as pelabresib, navitoclax, parsaclisib, or as monotherapies (navtemadlin) are evaluated in pivotal phase 3 trials. Imetelstat (telomerase inhibitor) is currently evaluated in the second line setting; OS was set as the primary endpoint, marking an unprecedented goal in MF trials, wherein SVR35 and TSS50 at 24 weeks have been typical endpoints heretofore. Transfusion independence may be considered another clinically meaningful endpoint in MF trials given its correlation with OS. Overall, therapeutics are at the cusp of an exponential expansion and advancements that will likely lead to the golden era in treatment of MF." @default.
• W4313555572 created "2023-01-06" @default.
• W4313555572 creator A5005670674 @default.
• W4313555572 creator A5080350639 @default.
• W4313555572 creator A5085521139 @default.
• W4313555572 date "2023-04-01" @default.
• W4313555572 modified "2023-10-14" @default.
• W4313555572 title "SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis" @default.
• W4313555572 cites W2017468796 @default.
• W4313555572 cites W2046567666 @default.
• W4313555572 cites W2084050646 @default.
• W4313555572 cites W2085253297 @default.
• W4313555572 cites W2089753725 @default.
• W4313555572 cites W2110444080 @default.
• W4313555572 cites W2114414564 @default.
• W4313555572 cites W2115351357 @default.
• W4313555572 cites W2121743767 @default.
• W4313555572 cites W2126532431 @default.
• W4313555572 cites W2149055075 @default.
• W4313555572 cites W2157066112 @default.
• W4313555572 cites W2525068643 @default.
• W4313555572 cites W2532748735 @default.
• W4313555572 cites W2558736960 @default.
• W4313555572 cites W2586215211 @default.
• W4313555572 cites W2613339929 @default.
• W4313555572 cites W2622547803 @default.
• W4313555572 cites W2731447759 @default.
• W4313555572 cites W2731573311 @default.
• W4313555572 cites W2754551124 @default.
• W4313555572 cites W2759277150 @default.
• W4313555572 cites W2771403719 @default.
• W4313555572 cites W2773899764 @default.
• W4313555572 cites W2776878294 @default.
• W4313555572 cites W2778275419 @default.
• W4313555572 cites W2784732912 @default.
• W4313555572 cites W2791240656 @default.
• W4313555572 cites W2791956198 @default.
• W4313555572 cites W2804579795 @default.
• W4313555572 cites W2954062012 @default.
• W4313555572 cites W2974691765 @default.
• W4313555572 cites W2976755053 @default.
• W4313555572 cites W2996087467 @default.
• W4313555572 cites W3008023739 @default.
• W4313555572 cites W3009670005 @default.
• W4313555572 cites W3010774459 @default.
• W4313555572 cites W3022617435 @default.
• W4313555572 cites W3026423379 @default.
• W4313555572 cites W3031846212 @default.
• W4313555572 cites W3040003446 @default.
• W4313555572 cites W3045198911 @default.
• W4313555572 cites W3048426426 @default.
• W4313555572 cites W3085980128 @default.
• W4313555572 cites W3092168378 @default.
• W4313555572 cites W3095090067 @default.
• W4313555572 cites W3095894988 @default.
• W4313555572 cites W3095897988 @default.
• W4313555572 cites W3096573094 @default.
• W4313555572 cites W3096827556 @default.
• W4313555572 cites W3097057554 @default.
• W4313555572 cites W3097624389 @default.
• W4313555572 cites W3107792394 @default.
• W4313555572 cites W3110102301 @default.
• W4313555572 cites W3110249225 @default.
• W4313555572 cites W3119071615 @default.
• W4313555572 cites W3134473205 @default.
• W4313555572 cites W3153573305 @default.
• W4313555572 cites W3165929791 @default.
• W4313555572 cites W3170159784 @default.
• W4313555572 cites W3173180464 @default.
• W4313555572 cites W3176941095 @default.
• W4313555572 cites W3196898846 @default.
• W4313555572 cites W3198816919 @default.
• W4313555572 cites W3200542521 @default.
• W4313555572 cites W3202626951 @default.
• W4313555572 cites W3204850429 @default.
• W4313555572 cites W3206662804 @default.
• W4313555572 cites W3213534400 @default.
• W4313555572 cites W3213980533 @default.
• W4313555572 cites W4206302502 @default.
• W4313555572 cites W4206994398 @default.
• W4313555572 cites W4211048388 @default.
• W4313555572 cites W4213345441 @default.
• W4313555572 cites W4213373081 @default.
• W4313555572 cites W4214638975 @default.
• W4313555572 cites W4214867747 @default.
• W4313555572 cites W4221096818 @default.
• W4313555572 cites W4225268854 @default.
• W4313555572 cites W4225643117 @default.
• W4313555572 cites W4225991971 @default.
• W4313555572 cites W4226064598 @default.
• W4313555572 cites W4229009918 @default.
• W4313555572 cites W4239376504 @default.
• W4313555572 cites W4280545603 @default.
• W4313555572 cites W4281295076 @default.
• W4313555572 cites W4281722646 @default.
• W4313555572 cites W4281775923 @default.
• W4313555572 cites W4282914934 @default.
• W4313555572 cites W4283311915 @default.

• next